News from eli lilly and company; boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 25, 2016, 08:30 ET
Eli Lilly and Company logo.

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on...

Nov 09, 2015, 10:45 ET
Eli Lilly and Company logo

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

 New sub-analysis data presented today showed the reduction in risk for hospitalization for heart failure or cardiovascular death with...

Nov 06, 2015, 08:00 ET
Eli Lilly and Company logo.

EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced that top-line renal results from the...

Oct 14, 2015, 08:30 ET
Eli Lilly and Company logo.

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced that Synjardy® (empagliflozin/metformin...

Sep 17, 2015, 11:46 ET

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company's (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the...

Aug 27, 2015, 10:30 ET
Eli Lilly and Company logo.

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Synjardy® (empagliflozin and metformin hydrochloride) tablets, from Boehringer...

Aug 20, 2015, 07:30 ET
Eli Lilly and Company logo.

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a...

May 27, 2015, 07:30 ET
Eli Lilly and Company logo.

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions®

 The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim (BIPI) and Eli Lilly and Company (NYSE:...

Mar 23, 2015, 08:30 ET
Eli Lilly and Company logo

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

 Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across...

Feb 02, 2015, 08:30 ET
Glyxambi® (empagliflozin/linagliptin) tablet packaging 10/5 mg (left). Glyxambi® (empagliflozin/linagliptin) tablet packaging 25/5 mg (right)

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer...

Nov 17, 2014, 16:00 ET
Eli Lilly and Company logo.

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers...

Oct 21, 2014, 08:30 ET
Eli Lilly and Company logo.

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release...

Sep 10, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

The European Commission (EC) granted marketing authorisation for Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim's insulin glargine...

Aug 26, 2014, 09:00 ET
Boehringer Ingelheim Pharmaceuticals, Inc. logo. (PRNewsFoto/Eli Lilly and Company)

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

 Jardiance® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite...

Aug 18, 2014, 17:32 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

 The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is...

Aug 04, 2014, 09:14 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

  The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data...

Aug 01, 2014, 23:26 ET
Jardiance (R)  (empagliflozin) 10 mg tablets* *The above image does not reflect the actual size of the tablet (PRNewsFoto/Eli Lilly and Company)

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA)...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

 The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound...

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...